Cargando…
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago. Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets. As a better understanding of MMP biology and inhibitor pharmacokinetic properties emerged, it bec...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769477/ https://www.ncbi.nlm.nih.gov/pubmed/31461880 http://dx.doi.org/10.3390/cells8090984 |